<DOC>
	<DOCNO>NCT00096551</DOCNO>
	<brief_summary>Background : - Pox viral vector induce PSA-specific T-cell response clinical response patient advanced prostate cancer . - Intratumoral vaccine recombinant fowlpox vector appear potent induce antitumor effect s.c. route administration , especially recombinant rF-vector give intratumorally preceded rV-recombinant give s.c . This may due : - Making tumor cell antigen present cell via upregulation antigen ( signal 1 ) costimulatory molecule ( signal 2 ) . - Making tumor cell susceptible kill via upregulation ICAM . - The increased expression perforin peptide-specific T cell come contact TRICOM-infected target . - Potentially allow immune system select tumor encode antigen generate polyvalent immune response . Objectives : - 1 : Safety feasibility intraprostatic vaccine strategy . - 2 : To assess change PSA-specific T-cell response measure ELISPOT assay . - 2 : To evaluate T-cell infiltration histologically patient pre- post-vaccine prostate biopsy . Eligibility : - Must either ) biopsy proven , locally recurrent prostate cancer follow local radiation define ASTRO consensus criterion 3 consecutively rise PSA level b ) refuse candidate local definitive therapy ( surgery radiation therapy ) clinically progressive disease androgen deprivation therapy ( eg . three increase PSA nadir , separate least one week ) . For patient previous RT , biopsy confirm local recurrence must do least 18 month completion RT . - Since may also generate systemic immune response , patient minimal extraprostatic disease may enrol . - Hepatic function : Bilirubin &lt; 1.5 mg/dl , AST ALT &lt; 2.5 time upper limit normal Design : - Dose escalation Phase I design . Each cohort consist 3-6 patient , cohort 4 &amp; 5 restrict include HLA-A2 + patient ; maximum accrual 30 - Patients cohort receive initial prim rV- PSA ( L155 ) /TRICOM rF-GM-CSF s.c. - The first two cohort utilize booster intraprostatic dose escalation rF-PSA ( L155 ) /TRICOM . - Third fourth cohort add dose escalation rF-GM-CSF along high dose rF-PSA ( L155 ) /TRICOM - Last ( 5th ) cohort u ...</brief_summary>
	<brief_title>A Phase I Feasibility Study Intraprostatic PSA-Based Vaccine Men With Prostate Cancer With Local Failure Following Radiotherapy Cryotherapy Clinical Progression Androgen Deprivation Therapy Absence Local Definitive Therapy</brief_title>
	<detailed_description>Background : - Pox viral vector induce PSA-specific T-cell response clinical response patient advanced prostate cancer . - Intratumoral vaccine recombinant fowlpox vector appear potent induce antitumor effect s.c. route administration , especially recombinant rF-vector give intratumorally preceded rV-recombinant give s.c . This may due : - Making tumor cell antigen present cell via upregulation antigen ( signal 1 ) costimulatory molecule ( signal 2 ) . - Making tumor cell susceptible kill via upregulation ICAM . - The increased expression perforin peptide-specific T cell come contact TRICOM-infected target . - Potentially allow immune system select tumor encode antigen generate polyvalent immune response . Objectives : - 1 : Safety feasibility intraprostatic vaccine strategy . - 2 : To assess change PSA-specific T-cell response measure ELISPOT assay . - 2 : To evaluate T-cell infiltration histologically patient pre- post-vaccine prostate biopsy . Eligibility : - Must either ) biopsy proven , locally recurrent prostate cancer follow local radiation define ASTRO consensus criterion 3 consecutively rise PSA level b ) refuse candidate local definitive therapy ( surgery radiation therapy ) clinically progressive disease androgen deprivation therapy ( eg . three increase PSA nadir , separate least one week ) . For patient previous RT , biopsy confirm local recurrence must do least 18 month completion RT . - Since may also generate systemic immune response , patient minimal extraprostatic disease may enrol . - Hepatic function : Bilirubin le 1.5 mg/dl , AST ALT less 2.5 time upper limit normal . Design : - Dose escalation Phase I design . Each cohort consist 3-6 patient ; maximum accrual 30 - Patients cohort receive initial prim rV- PSA ( L155 ) /TRICOM rF-GM-CSF s.c. - The first two cohort utilize booster intraprostatic dose escalation rF-PSA ( L155 ) /TRICOM . - Third fourth cohort add dose escalation rF-GM-CSF along high dose rF-PSA ( L155 ) /TRICOM . - Last ( 5th ) cohort utilizes booster intraprostatic vaccine ( rF-PSA ( L155 ) /TRICOM rF-GM-CSF ) simultaneous identical booster vaccine give s.c .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>INCLUSION CRITERIA : A. Histopathological documentation prostate cancer confirm Laboratory Pathology : NIH Clinical Center , National Institutes Health ( NIH ) , National Naval Medical Center , Walter Reed Army Medical Center prior start study . If pathologic specimen available , patient may enroll pathologist 's report show histologic diagnosis prostate cancer clinical course consistent disease . B . Must either ) biopsy proven , locally recurrent prostate cancer follow local radiation cyrotherapy define ASTRO consensus criterion 3 consecutively rise PSA level b ) refuse candidate local definitive therapy ( surgery radiation therapy ) clinically progressive disease androgen deprivation therapy ( e.g. , three increase PSA nadir , separate least one week ) . For patient previous RT , biopsy confirm local recurrence must do least 18 month completion RT . Since may also generate systemic immune response , patient minimal extraprostatic disease may enrol . C. Agree use adequate contraception prior study entry least 4 month follow last vaccine injection . D. Life expectancy great equal 6 month . E. ECOG performance status 0 2 ( see Appendix A ) . F. Recovered acute toxicity relate prior therapy , include surgery , radiation ( treatment must complete least 4 week prior eligible study ) . G. Hematological eligibility parameter ( within 16 day start therapy , see Appendix D ) . Granulocyte count great equal 1,500/mm3 Platelet count great equal 100,000/mm3 Lymphocyte count great equal 500/mm3 Hgb great equal 10 Gm/dL H. Biochemical eligibility parameter ( within 16 day start therapy ) : A 24hour urine collection baseline measure creatinine clearance , protein electrolyte . CrCl great 60mL/min , proteinuria less 1000 milligram per 24 hour , abnormal sediment . Serum creatinine normal limit OR creatinine clearance 24 hour urine collection great 60 mL/min . For patient able obtain accurate collection , calculate creatinine clearance urine analysis protein may use . Any abnormality sediment presence hematuria without likely underlying cause prompt investigator consider evaluation nephrologist urologist evidence underlie renal pathology . Patients may eligible underlie cause abnormality determine nonrenal . Hepatic function : Bilirubin equal 1.5 mg/dL patient Gilbert 's syndrome , total bilirubin less equal 3.0 mg/dL , AST ALT less 2.5 time upper limit normal . I . No active malignancy within past 12 month ( exception nonmelanoma skin cancer carcinoma situ bladder ) life threaten illness . J . Willing travel NIH followup visit . K. 18 year age great . L. Vaccinianaive vaccinia immune . M. Able understand sign inform consent . N. Tested HLAA2 ; however , result test affect entry study . This test may draw patient 's refer physician time referral ( see Screening Consent HLA type ) . This consent mail patient discuss patient . The signed consent sign nonfamily member witness mail assign research nurse NIH Clinical Center . O. Concurrent hormonal therapy allow . P. PT / PTT drawn prior invasive protocol relate procedure ( i.e. , prostate biopsy intraprostatic injection ) standard clinical guideline follow . EXCLUSION CRITERIA : A . Patients evidence immunocompromised list . Human immunodeficiency virus positivity due potential decrease tolerance may risk severe side effect . Active autoimmune disease , Addison 's disease , Hashimoto 's thyroiditis , systemic lupus erythematous , Sjogren syndrome , scleroderma , myasthenia gravis , Goodpasture syndrome active Grave 's disease . Patients history autoimmunity require systemic immunosuppressive therapy threaten vital organ function include CNS , heart , lung , kidney , skin , GI tract allow . Hepatitis B C positivity . Concurrent use systemic steroid , except physiologic dos systemic steroid replacement local ( topical , nasal , inhale ) steroid use . Steroid eye drop contraindicate least 2 week prior vaccinia vaccination least 4 week post vaccinia vaccination . B . History allergy untoward reaction prior vaccination vaccinia virus component vaccinia vaccine regimen . C. Must able avoid close household contact ( close household contact share housing close physical contact ) least three week recombinant vaccinia vaccination person active history eczema eczematoid skin disorder ; acute , chronic exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) condition resolve ; pregnant nursing woman ; child 3 year age ; immunodeficient immunosuppressed person ( disease therapy ) , include HIV infection . D. Serious intercurrent medical illness would interfere ability patient carry treatment program , include , limited , inflammatory bowel disease , Crohn 's disease , ulcerative colitis , active diverticulitis . E. Patients cardiac disease fatigue , palpitation , dyspnea angina ordinary physical activity ( New York Heart Association class 2 great ) eligible . F. Patients objective evidence congestive heart failure physical exam image eligible . G. Patients pulmonary disease fatigue dyspnea ordinary physical activity eligible . H. Concurrent chemotherapy . I. Clinically active brain metastasis , history seizure , encephalitis , multiple sclerosis . J . Serious hypersensitivity reaction egg product .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 25, 2011</verification_date>
	<keyword>Biochemical Failure</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>TRICOM</keyword>
	<keyword>Pox-virus</keyword>
	<keyword>Fowlpox</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>